Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Optimized synthetic consensus immunogenic compositions targeting the follicle stimulating hormone receptor (FSHR)

A technology of immunogenicity and immunogenic fragments, applied in the field of administering the immunogenic composition, capable of solving problems such as no change in survival rate

Pending Publication Date: 2019-08-13
THE TRUSTEES OF THE UNIV OF PENNSYLVANIA +2
View PDF84 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite advances in surgery and chemotherapy, five-year survival rates have changed little over the past 40 years

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Optimized synthetic consensus immunogenic compositions targeting the follicle stimulating hormone receptor (FSHR)
  • Optimized synthetic consensus immunogenic compositions targeting the follicle stimulating hormone receptor (FSHR)
  • Optimized synthetic consensus immunogenic compositions targeting the follicle stimulating hormone receptor (FSHR)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0251] Example 1: Optimized Consensus FSHR Immunogenic Compositions

[0252] DNA vaccines have potent antitumor activity in humans. Synthetic consensus DNA vaccines have been designed to break tolerance and redirect the immune system to the FSHR protein. Consensus-based DNA vaccines have shown promise in the clinic, achieving clearance of cervical intraepithelial neoplasia. The advantage of this approach over peptide vaccines is that it can elicit immune responses against multiple peptides derived from endogenous natural cleavage of proteins and can be presented in all different variants of MHC class I and II.

[0253] DNA cancer vaccines have proven successful against tumors with viral antigens, however, this success has not translated into effective responses against aggressive and common cancers such as ovarian cancer. One of the limitations is the lack of targetable antigens selectively expressed by tumor cells but not healthy tissues, which can lead to lethal adverse ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided herein is an immunogenic composition comprising a synthetic consensus antigen to Follicle Stimulating Hormone Receptor (FSHR) protein which is abundant in many ovarian cancer sub-types. Alsodisclosed herein is a method of treating a tumor associated pathology in a subject in need thereof, by administering the immunogenic composition to the subject.

Description

[0001] Cross References to Related Applications [0002] This application benefits from US Provisional Application No. 62 / 380,766, filed August 29, 2016, which is hereby incorporated by reference in its entirety. technical field [0003] The present invention relates to immunogenic compositions targeting follicle stimulating hormone receptor (FSHR), and methods of administering said immunogenic compositions. Background technique [0004] Epithelial ovarian cancer is one of the deadliest malignancies, killing >14,000 women annually in the United States. Despite advances in surgical approaches and chemotherapy, five-year survival rates have changed little over the past 40 years. Ovarian cancer is an immunogenic tumor, and T cell infiltration is repeatedly associated with better prognosis (Zhang et al., N Engl J Med. 2003, 348:203-213). However, only about 50% of tumors present infiltrating T cells (Zhang et al., N Engl J Med. 2003, 348:203-213). Thus, immunotherapy aimed...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61K38/24C07K16/30
CPCA61K38/1796A61K39/0011A61K2039/53A61P35/00A61K39/001102C07K14/723A61K2039/5258A61K2039/555A61K2039/54A61K2039/892A61K2039/5256A61K2039/572
Inventor 大卫·韦纳阿尔弗雷多·佩拉莱斯·普查尔特严健安娜·玛丽亚·斯莱格
Owner THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com